The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
ASH 2025 Highlights: Top Hematology Research Abstracts, Selected by Field Experts
By The Cancer News Team
A curated expert review of the most impactful leukemia and myeloproliferative neoplasm (MPN) research abstracts presented at the 2025 American Society of Hematology (ASH) Annual Meeting.
ASH 2025 Highlights: Top Hematology Research Abstracts, Selected by Field Experts
By The Cancer News Team
A curated expert review of the most impactful leukemia and myeloproliferative neoplasm (MPN) research abstracts presented at the 2025 American Society of Hematology (ASH) Annual Meeting.
ASH 2025 Highlights: Top Hematology Research Abstracts, Selected by Field Experts
By The Cancer News Team
A curated expert review of the most impactful leukemia and myeloproliferative neoplasm (MPN) research abstracts presented at the 2025 American Society of Hematology (ASH) Annual Meeting.
Understanding PALB2 Mutations in Pancreatic Cancer
By Jonathan W Lee, MD, MSc
November marks Pancreatic Cancer Awareness Month, a time to shine a light on one of oncology's most challenging diseases.
Understanding PALB2 Mutations in Pancreatic Cancer
By Jonathan W Lee, MD, MSc
November marks Pancreatic Cancer Awareness Month, a time to shine a light on one of oncology's most challenging diseases.
Understanding PALB2 Mutations in Pancreatic Cancer
By Jonathan W Lee, MD, MSc
November marks Pancreatic Cancer Awareness Month, a time to shine a light on one of oncology's most challenging diseases.
Top 8 Takeaways on mRNA Cancer Vaccines and Personalized Immunotherapy Development
By The Cancer News Team
A comprehensive summary of key insights on mRNA cancer vaccines and personalized immunotherapy development presented at the 5th Binaytara Precision Oncology Summit.
Top 8 Takeaways on mRNA Cancer Vaccines and Personalized Immunotherapy Development
By The Cancer News Team
A comprehensive summary of key insights on mRNA cancer vaccines and personalized immunotherapy development presented at the 5th Binaytara Precision Oncology Summit.
Top 8 Takeaways on mRNA Cancer Vaccines and Personalized Immunotherapy Development
By The Cancer News Team
A comprehensive summary of key insights on mRNA cancer vaccines and personalized immunotherapy development presented at the 5th Binaytara Precision Oncology Summit.
The Future of Precision Oncology: Biomarkers and Drug Development
By The Cancer News Team
A comprehensive overview of emerging precision oncology innovations, focusing on biomarkers, drug development challenges, and the future of targeted cancer therapies.
The Future of Precision Oncology: Biomarkers and Drug Development
By The Cancer News Team
A comprehensive overview of emerging precision oncology innovations, focusing on biomarkers, drug development challenges, and the future of targeted cancer therapies.
The Future of Precision Oncology: Biomarkers and Drug Development
By The Cancer News Team
A comprehensive overview of emerging precision oncology innovations, focusing on biomarkers, drug development challenges, and the future of targeted cancer therapies.
Molecular Tumor Board 2: Interesting and Challenging Cases in Precision Oncology
By The Cancer News Team
This article summarizes the transcript from Session 11 of the 5th Binaytara Precision Oncology Summit
Molecular Tumor Board 2: Interesting and Challenging Cases in Precision Oncology
By The Cancer News Team
This article summarizes the transcript from Session 11 of the 5th Binaytara Precision Oncology Summit
Molecular Tumor Board 2: Interesting and Challenging Cases in Precision Oncology
By The Cancer News Team
This article summarizes the transcript from Session 11 of the 5th Binaytara Precision Oncology Summit
$40 Test Could Save Lives: Researcher Cracks Code on Aggressive Leukemia Affecting One-Third of Asian Patients
By The Cancer News Team
Dr. Dikshat Gupta’s $40 diagnostic test for Ph-like ALL offers a groundbreaking, affordable solution to detect aggressive leukemia subtypes common in Asian populations, advancing equitable cancer care.
$40 Test Could Save Lives: Researcher Cracks Code on Aggressive Leukemia Affecting One-Third of Asian Patients
By The Cancer News Team
Dr. Dikshat Gupta’s $40 diagnostic test for Ph-like ALL offers a groundbreaking, affordable solution to detect aggressive leukemia subtypes common in Asian populations, advancing equitable cancer care.
$40 Test Could Save Lives: Researcher Cracks Code on Aggressive Leukemia Affecting One-Third of Asian Patients
By The Cancer News Team
Dr. Dikshat Gupta’s $40 diagnostic test for Ph-like ALL offers a groundbreaking, affordable solution to detect aggressive leukemia subtypes common in Asian populations, advancing equitable cancer care.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.